Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC in retinitis pigmentosa
NCT03063021Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Feb 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of acetylcysteine in retinitis pigmentosa (RP) (2 arms), sponsored by Johns Hopkins University. Primary endpoint: Assessment of safety and tolerability of N-Acetylcysteine at 10 months. Started Feb 2017; status: completed.
02
Drugs
acetylcysteine
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT03063021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03063021.